Table 1 Patient characteristics (N = 32,492)
From: Renal function deterioration in adult patients with type-2 diabetes
|  | All patients with T2DM (n = 413,239) mean ± SD or % | Subgroup (n = 32,492) mean ± SD or % |
|---|---|---|
Age, years | 68.2 ± 12.9 | 66.3 ± 11.4 |
Male gender, % | 52.8 | 52.6 |
Body mass index, kg/m2 | 31.0 ± 6.7 | 31.7 ± 6.2 |
Diabetes duration, years | 10.5 ± 9.2 | 11.3 ± 8.5 |
HbA1c, % | 7.6 ± 1.9 | 7.0 ± 1.0 |
Antidiabetic drug treatment | ||
 Insulin, % | 47.1 | 45.8 |
 Metformin, % | 35.7 | 56.7 |
 DPP4-inhibitors, % | 13.8 | 16.7 |
 Sulfonylurea, % | 10.6 | 19.4 |
 Glinides, % | 3.2 | 7.5 |
 Acarbose, % | 1.1 | 2.1 |
 Sensitizers, % | 1.0 | 4.5 |
 GLP-1 analogues, % | 2.9 | 6.6 |
 SGLT-2 inhibitors, % | 2.5 | 4.2 |
Hypertension, % | 74.7 | 88.1 |
 Syst. blood pressure, mmHg | 135.4 ± 18.3 | 135.5 ± 12.5 |
 Diast. blood pressure, mmHg | 77.4 ± 10.6 | 78.6 ± 7.3 |
 Antihypertensive drug treatment, % | 52.1 | 67.0 |
  ACEi, % | 28.2 | 37.8 |
  ARBs, % | 11.3 | 21.6 |
  Betablockers, % | 28.4 | 35.1 |
  Calcium channel blockers, % | 14.7 | 23.7 |
  Diuretics, % | 28.7 | 31.8 |
Dyslipidemia, % | 47.6 | 66.1 |
Kidney parameters | ||
 eGFR, mL/min/1.73 m2 | 68.2 ± 26.5 | 76.7 ± 21.7 |
 Serum potassium, mmol/L | 4.3 ± 0.6 | 4.4 ± 0.5 |
Comorbidity at baseline | ||
 Myocardial infarction, % | 8.1 | 9.7 |
 Stroke, % | 7.3 | 8.0 |
 Heart failure, % | 5.7 | 9.2 |
 Peripheral artery disease, % | 16.3 | 32.8 |
 Major amputation, % | 0.9 | 0.8 |
 Minor amputation, % | 2.2 | 1.9 |
 Diabetic neuropathy, % | 43.6 | 69.5 |
 Diabetic foot syndrome, % | 11.6 | 25.1 |
 Diabetic retinopathy, % | 4.8 | 13.5 |